What makes Daejeon Panax ginseng different from regular Korean ginseng?

Daejeon Panax is a selectively bred cultivar of Panax ginseng developed in South Korea's breeding programs specifically to enhance total ginsenoside content, particularly the concentrations of Rb1, Rg1, and Rg3 compared to standard field-grown varieties. This agricultural optimization aims to improve raw material potency, though no published human trials have compared Daejeon cultivar outcomes directly against conventional Panax ginseng in clinical settings.

What ginsenosides are found in Daejeon Panax ginseng?

Daejeon Panax ginseng contains the full spectrum of Panax ginseng ginsenosides, including protopanaxadiol-type saponins (Rb1, Rb2, Rc, Rd) and protopanaxatriol-type saponins (Rg1, Re, Rf), with breeding programs targeting elevated total ginsenoside yield. Ginsenoside Rg3, associated with antioxidant and potential anti-inflammatory activity, is also present and is particularly concentrated in red ginseng preparations that involve steaming and drying of the root.

Is there clinical evidence for Daejeon Panax ginseng specifically?

Currently, no published human clinical trials isolate Daejeon Panax as a distinct cultivar for testing; all available clinical data comes from broader Panax ginseng research using Korean or Chinese ginseng populations not identified by cultivar name. While Panax ginseng has demonstrated cognitive, adaptogenic, and glycemic benefits in controlled trials, these findings should not be assumed to apply identically to Daejeon varieties until cultivar-specific studies are conducted.

What is the recommended dosage of Panax ginseng extract?

Standard research dosages for Panax ginseng standardized extract (typically 4–7% total ginsenosides) range from 200 mg to 400 mg per day, often divided into two doses. Higher doses up to 900 mg/day have been used in some trials assessing immune modulation, but doses above 600 mg/day are associated with increased incidence of side effects including insomnia and mild hypertension, and no Daejeon cultivar-specific dosing recommendations currently exist.

Can Daejeon Panax ginseng interact with blood thinners like warfarin?

Yes, Panax ginseng has documented pharmacokinetic and pharmacodynamic interactions with warfarin; a case report and subsequent pharmacological studies indicate ginseng can reduce warfarin's anticoagulant effect by inducing CYP2C9-mediated metabolism, lowering INR values. Patients on anticoagulant therapy should consult a healthcare provider before using any Panax ginseng supplement, including Daejeon cultivar products, and INR should be monitored closely if concurrent use is initiated.

How does Daejeon Panax ginseng's ginsenoside profile compare to wild-harvested ginseng?

Daejeon Panax ginseng is a cultivated variety bred specifically to enhance ginsenoside content compared to wild-harvested specimens. Wild ginseng varieties typically contain lower and more variable ginsenoside concentrations due to uncontrolled growing conditions. The controlled agricultural breeding programs used for Daejeon cultivars aim to produce more consistent and higher concentrations of specific ginsenosides, though both sources contain the same ginsenoside compounds.

Is Daejeon Panax ginseng safe for people taking diabetes medications?

While traditional use suggests ginseng may support metabolic function, there is no specific clinical evidence documenting interactions between Daejeon Panax ginseng and diabetes medications. Like other ginseng varieties, it may theoretically affect blood sugar levels, so individuals on diabetes medications should consult their healthcare provider before supplementing. No controlled human trials have specifically evaluated this combination with Daejeon cultivars.

Why is disease resistance important when choosing a Daejeon Panax ginseng supplement?

Disease-resistant Daejeon cultivars (such as those with 61.1% resistance to root rot) indicate a more stable agricultural supply and potentially more consistent product quality. These resistant strains are less likely to be treated with fungicides or experience contamination from plant pathogens during cultivation. From a sourcing perspective, disease-resistant cultivars support more sustainable and reliable production of ginseng supplements.

Daejeon Panax (Panax ginseng)

Daejeon Panax is a cultivated variety of Panax ginseng developed through Korean breeding programs to produce elevated concentrations of ginsenosides, particularly Rb1, Rg1, and Rg3, the primary bioactive saponins. These ginsenosides interact with glucocorticoid receptors and modulate the HPA axis, underlying the adaptogenic and neuroprotective properties associated with Panax ginseng species broadly.

Category: Other Evidence: 2/10 Tier: Traditional

Daejeon Panax (Panax ginseng) — Hermetica Encyclopedia

Origin & History

Daejeon Panax refers to Panax ginseng cultivars developed in the Daejeon region of South Korea through selective breeding programs using local Korean landraces like Hwangsook, Chungkyung, and Jakyung. These cultivars are grown for 4-6 years under shaded conditions and processed into raw, white (dried), or red ginseng (steamed and dried) forms. Breeding programs focus on enhancing root yield, disease resistance, and ginsenoside content.

Historical & Cultural Context

Panax ginseng, including Korean cultivars from regions like Daejeon, has been used in Traditional Korean Medicine for over 2,000 years as an adaptogen for vitality, fatigue, and immune support. Modern cultivars stem from landraces selected since at least the early 20th century in Korea, with Daejeon serving as a key center for ginseng breeding and production.

Health Benefits

• No specific health benefits documented - no human clinical trials on Daejeon Panax cultivars found in research
• Traditional Korean Medicine use suggests adaptogenic properties - traditional use only, no clinical evidence
• Breeding programs enhance ginsenoside content - agricultural data only, no human studies
• Disease-resistant cultivars (61.1% resistance to root rot) - applies to plant cultivation, not human health
• Higher root yields (23-73.7g per 3-4 year root) - agricultural metric only, no health implications studied

How It Works

Ginsenosides from Panax ginseng, including those concentrated in Daejeon cultivars, bind to glucocorticoid and estrogen receptors, modulating cortisol secretion via the hypothalamic-pituitary-adrenal (HPA) axis. Ginsenoside Rg1 upregulates nitric oxide synthase (eNOS) in vascular endothelium and stimulates BDNF expression in hippocampal neurons, supporting cognitive function. Ginsenoside Rb1 inhibits neuronal apoptosis through Bcl-2 pathway upregulation and attenuates oxidative stress by activating Nrf2-mediated antioxidant enzymes including superoxide dismutase and catalase.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on Daejeon Panax cultivars were found in the research. The available data focuses exclusively on agricultural breeding characteristics and cultivation methods rather than clinical efficacy.

Clinical Summary

No human clinical trials have been conducted specifically on Daejeon Panax cultivars as a distinct agricultural variety, making direct clinical evidence unavailable for this specific strain. Available evidence is extrapolated from broader Panax ginseng research, which includes randomized controlled trials such as a 2010 RCT (n=30) showing standardized Korean Red Ginseng improved cognitive performance on the Serial Sevens test versus placebo. Adaptogenic and fatigue-reduction effects have been documented in Panax ginseng populations using 200–400 mg/day standardized extracts, but these findings cannot be attributed specifically to Daejeon cultivar chemistry without cultivar-specific trials. The elevated ginsenoside profile of Daejeon varieties is supported by agricultural phytochemical assays, not clinical outcome data.

Nutritional Profile

Daejeon Panax (Panax ginseng) shares the general nutritional composition of cultivated Korean ginseng root. Dry root contains approximately 60-70% carbohydrates (primarily starch 20-40%, water-soluble polysaccharides 10-20%, pectin), 12-16% protein (including arginine, glutamic acid, aspartic acid as dominant amino acids), 1-2% fat (fatty acids including linolenic, palmitic, stearic acid), and 2-7% fiber. Key bioactive ginsenosides (triterpenoid saponins) are the primary compounds of interest, with total ginsenoside content typically ranging 2-6% in standard Panax ginseng dry root; Daejeon breeding programs are specifically noted to have enhanced ginsenoside concentrations above standard cultivar averages, though precise Daejeon-specific figures are not publicly quantified in available literature. Dominant ginsenosides include Rb1, Rb2, Rc, Rd (protopanaxadiol group) and Rg1, Re, Rf (protopanaxatriol group). Polyacetylenes (panaxynol, panaxydol) are present at trace levels (~0.1%). Mineral content includes potassium (~600 mg/100g dry weight), calcium (~80 mg/100g), magnesium (~40 mg/100g), phosphorus (~300 mg/100g), and trace iron, zinc, manganese. Vitamins are limited: small amounts of B vitamins (thiamine, riboflavin, B6) and vitamin C (~2-5 mg/100g fresh). Bioavailability of ginsenosides is moderate without gut microbiome conversion to active metabolites (e.g., compound K); bioavailability is enhanced by fermentation or heat processing (red ginseng processing). Disease-resistant cultivar traits do not alter nutritional composition meaningfully.

Preparation & Dosage

No clinically studied dosage ranges are available for Daejeon Panax, as no human trials have been documented. Cultivar development data emphasizes agricultural traits like root weight rather than extract standardization or therapeutic dosing. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients documented in research

Safety & Interactions

Panax ginseng extracts are generally well tolerated at 200–400 mg/day, with the most commonly reported side effects including insomnia, headache, gastrointestinal upset, and mild hypertension at higher doses. Ginseng inhibits CYP3A4 and CYP2C9 enzymes and carries clinically relevant interactions with warfarin, potentially reducing INR, as well as interactions with MAO inhibitors, antidiabetic medications, and immunosuppressants such as cyclosporine. Ginseng is contraindicated in individuals with hormone-sensitive conditions including estrogen receptor-positive cancers due to estrogen-like activity of certain ginsenosides. Use during pregnancy and breastfeeding is not recommended due to insufficient safety data and animal studies suggesting teratogenic potential at high doses.